Melatonin
Melatonin is strongest for circadian timing, with Ferracioli-Oda 2013 finding sleep latency improved by 7.06 minutes across 19 RCTs. The broader antioxidant and hormone-signal story is interesting, but the most practical use is still timing, dose, and light context.
Melatonin scored 7.3 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Exogenous Metabolite.
What It Is
Melatonin reduced sleep-onset latency by 7.06 minutes across 19 RCTs in Ferracioli-Oda et al. 2013, but the stronger use case is often circadian rhythm alignment. Melatonin earns a strong-recommend score because conventional adult doses have broad evidence, low cost, fast feedback, and a favorable safety profile when product quality and timing are handled well. Melatonin also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism. The score does not tell a reader to use Melatonin; the score shows where the evidence, practical burden, and safety concerns currently meet. That matters because the same intervention can look attractive in one subgroup and poorly matched in another.
The practical distinction matters because Melatonin can mean a tightly regulated product in one setting and a loosely sourced product in another. The BioHarmony score is therefore a mixed-context estimate: the upside reflects the verified human evidence, while the downside reflects the risks that remain after separating intrinsic pharmacology from access and sourcing.
Additional evidence links in this report include 0.5 mg vs 3 mg phase response. Blind free-running circadian rhythm RCT. Autism sleep latency and total sleep time.
Pediatric prolonged-release RCT. Supplement quality variability. Gummy-label accuracy..
Those comparisons help place Melatonin beside interventions with different tradeoffs in sleep, skin, immune, recovery, and peptide-adjacent use cases.
Across 19 RCTs, melatonin reduced sleep-onset latency by 7.06 minutes and increased total sleep time by 8.25 minutes.
In autism-spectrum sleep trials, melatonin reduced sleep-onset latency by 39 minutes versus placebo and increased total sleep time by 44 minutes.
Rossignol and Frye, Developmental Medicine and Child Neurology
"Melatonin is not a hypnotic."
"Melatonin has both chronobiotic and soporific effects."
"Products contained from -83% to +478% of the labeled content."
Terminology
Melatonin terminology matters because dose, timing, and goal change the meaning of the intervention. Melatonin at 0.3 mg for circadian phase shifting is not the same practical intervention as 10 mg for sleepiness or 20 mg used in a specialty context. The report covers conventional doses from 0.3 to 20 mg across sleep quality, circadian rhythm, jet lag, antioxidant biology, anxiety, immune-function, prenatal, pediatric, and geriatric contexts. High-dose melatonin above 20 mg gets its own report.Melatonin also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism For efficacy, that means the claim needs a direct endpoint match..The score does not tell a reader to use Melatonin; the score shows where the evidence, practical burden, and safety concerns currently meet For efficacy, that means the claim needs a direct endpoint match..That matters because the same intervention can look attractive in one subgroup and poorly matched in another For efficacy, that means the claim needs a direct endpoint match..
- Clinical Range: The dose range used in controlled trials, labels, or systematic reviews. - Anecdotal Range: The dose range common in community use, practitioner protocols, or gray-market practice when that differs from clinical research. - MC1R: Melanocortin 1 receptor, the skin-pigment receptor most relevant to eumelanin biology. - MC4R: Melanocortin 4 receptor, a central nervous system receptor involved in appetite and sexual-response signaling. - DLMO: Dim-light melatonin onset, a circadian marker used to time melatonin for phase shifting. - RCT: Randomized controlled trial, the strongest routine human-evidence design for intervention effects. - PRES: Posterior reversible encephalopathy syndrome, a rare neurologic emergency reported in a melanotan case report. - USP-Verified: A supplement quality marker showing independent checks for identity, potency, and contaminants.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | tablet, capsule, liquid, gummy | 0.3 to 20 mg | 0.3 to 10 mg most common |
| sublingual | lozenge or liquid | not separately established | 0.3 to 5 mg |
Protocols
Circadian Phase Advance Clinical
- Dose
- 0.5 to 3 mg
- Frequency
- Daily
- Duration
- Several nights to weeks
Timing relative to DLMO matters more than dose.
Jet Lag Clinical
- Dose
- 0.5 to 5 mg
- Frequency
- Destination bedtime
- Duration
- Several days
Best for eastward travel and sleep timing.
General Sleep Support Mixed
- Dose
- 0.3 to 5 mg
- Frequency
- Evening
- Duration
- As needed or short term
Higher doses often add grogginess without proportional benefit.
How this score is calculated →
Upside contribution: 2.90
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.6 | 0.900 | |
| Breadth of Benefits | 15% | 4.1 | 0.615 | |
| Evidence Quality | 25% | 4.2 | 1.050 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 3.0 | 0.300 | |
| Bioindividuality Upside | 15% | 4.2 | 0.630 | |
| Total | 3.895 |
Upside Rationale
Melatonin upside comes from matching the molecule to the right job: timing the clock, easing sleep onset, and supporting antioxidant biology in selected contexts. Burgess et al. 2010 showed 0.5 mg and 3 mg doses can produce similar circadian phase shifts when timed correctly, which is why bigger doses are not automatically better. Melatonin's breadth is unusually wide, but the average insomnia effect is modest. 6/5.0
Efficacy (3.6/5.0): Melatonin efficacy is moderate because sleep effects are statistically reliable but usually small, while circadian timing effects are stronger when dosing is timed correctly. Brzezinski et al. 2005 found sleep latency improved by 4.0 minutes and total sleep time by 12.8 minutes. Melatonin is useful, but not a knockout sedative.
Breadth of Benefits (4.1/5.0): Melatonin breadth is high because conventional dosing touches sleep quality, circadian rhythm, jet lag, pediatric autism insomnia, perioperative anxiety, antioxidant biology, blood pressure, immune signaling, and specialty populations. Melatonin earns breadth through many modest signals rather than one dramatic effect. The report keeps those use cases separate so sleep does not swallow the whole evaluation.
Evidence Quality (4.2/5.0): Melatonin evidence quality is strong for a supplement because multiple meta-analyses, Cochrane reviews, pediatric RCTs, circadian guidelines, and safety studies exist. Auld et al. 2017 and AASM guidance also keep expectations sober. The evidence score is not perfect because supplement quality and population-specific long-term data remain uneven.
Speed of Onset (4.0/5.0): Melatonin speed is high because sleepiness and phase-shift signals can appear the same night or within several nights. Mundey et al. 2005 supports phase-dependent delayed-sleep treatment, which is a timing effect rather than a slow nutrient-repletion effect. Fast feedback helps users adjust timing, dose, and morning grogginess quickly.
Durability (3.0/5.0): Melatonin durability is moderate because circadian entrainment can persist when light behavior and schedule reinforce it, while the acute sleepiness effect usually requires continued timing. Melatonin does not fix a chaotic light environment by itself. Benefits fade when evening light, irregular sleep, travel, or shift work keeps pushing the clock in the opposite direction.
Bioindividuality Upside (4.2/5.0): Melatonin bioindividuality is high because age, chronotype, DLMO timing, light exposure, blindness, autism, ADHD, caffeine timing, glucose phenotype, and medications predict response. Garaulet et al. 2015 also shows MTNR1B genotype can worsen glucose tolerance after melatonin. Melatonin is a good example of an intervention where personalization changes the result.
Downside contribution: 0.62 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.6 | 0.480 | |
| Side Effect Profile | 15% | 1.7 | 0.255 | |
| Financial Cost | 5% | 1.3 | 0.065 | |
| Time/Effort Burden | 5% | 1.3 | 0.065 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.3 | 0.195 | |
| Reversibility | 25% | 1.3 | 0.325 | |
| Total | 1.460 | |||
| Harm subtotal × 1.4 | 1.757 | |||
| Opportunity subtotal × 1.0 | 0.205 | |||
| Combined downside | 1.962 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.622 |
Downside Rationale
Melatonin downside is usually mild for adults using conventional doses, but the main practical risks are mistimed dosing, next-day grogginess, product-label inaccuracy, pediatric accidental ingestion, bipolar-spectrum mood destabilization, and glucose or blood-pressure interactions. Cohen et al. 2023 found many gummies did not match their labels, and Rubio-Sastre et al. 2014 showed acute melatonin can impair glucose tolerance. Those risks matter without turning melatonin into a high-risk supplement. 6/5.0
Safety Risk (1.6/5.0): Melatonin Safety Risk is low for adults using USP-verified synthetic products at conventional doses, but population-specific risks matter. Pediatric accidental ingestion, bipolar-spectrum mania risk, glucose tolerance, hypotension, fluvoxamine interaction, and pregnancy uncertainty belong in the verdict. Melatonin does not need a severe adult safety floor when quality and dose stay conventional.
Side Effect Profile (1.7/5.0): Melatonin side effects are usually mild: morning grogginess, vivid dreams, headache, dizziness, nausea, and next-day sluggishness. Melatonin becomes more annoying when doses climb without a timing reason. The score also reflects supplement inconsistency because an intended 1 mg gummy may deliver far more, making side effects look mysterious when the real issue is labeling.
Financial Cost (1.3/5.0): Melatonin cost is low because synthetic melatonin is widely available and inexpensive. Melatonin quality varies, so the best value is usually a simple third-party-tested capsule or tablet rather than novelty gummies. Even with a better brand, the monthly cost remains low compared with peptides, devices, prescription sleep drugs, or intensive circadian programs.
Time/Effort Burden (1.3/5.0): Melatonin effort is low because oral dosing is simple, but correct timing takes thought. Melatonin works best when paired with light management, consistent wake time, and dose restraint. The effort score is therefore slightly above trivial: swallowing a pill is easy, while using the molecule as a clock signal takes more precision.
Opportunity Cost (1.5/5.0): Melatonin opportunity cost is low to moderate because it can distract from morning light, evening darkness, caffeine timing, alcohol reduction, sleep apnea evaluation, and behavioral sleep work. Melatonin is cheap and reversible, so the opportunity cost is not large. The bigger problem is using escalating doses when the actual issue is circadian hygiene.
Dependency/Withdrawal (1.3/5.0): Melatonin dependency risk is low because conventional doses do not produce a classic withdrawal syndrome or known shutdown of natural production in adults. Some users experience rebound insomnia when stopping because the original sleep schedule problem returns.
Reversibility (1.3/5.0): Melatonin reversibility is strong because most side effects resolve within a day or two after stopping or lowering dose. Melatonin's main irreversibility concern is accidental pediatric overdose or a mood episode in a vulnerable person, which is why the report emphasizes storage and bipolar caution. For typical adult use, reversibility is favorable.
Verdict
Melatonin is one of the more useful low-cost supplements when the target is circadian timing, jet lag, delayed sleep phase, or carefully selected sleep-onset support. Melatonin is less impressive when used as a blunt sedative, especially at escalating doses that create grogginess. The 7.3 score reflects broad but not dramatic benefits, unusually good reversibility, strong timing logic, and enough safety caveats to keep the report grounded.Melatonin also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism For speed, short-term noticeability is separated from durable value.The score does not tell a reader to use Melatonin; the score shows where the evidence, practical burden, and safety concerns currently meet For speed, short-term noticeability is separated from durable value.That matters because the same intervention can look attractive in one subgroup and poorly matched in another For speed, short-term noticeability is separated from durable value.
✅ Best for: Melatonin is best for travelers crossing time zones, delayed sleep phase, blind or low-light circadian disruption, older adults with low nighttime melatonin, autistic children with supervised insomnia protocols, and adults who need a clock signal rather than a sedative. Melatonin also fits users who want an antioxidant-adjacent supplement with a large human safety footprint at conventional doses.
❌ Avoid if: Melatonin should be avoided or supervised in bipolar disorder, pregnancy, lactation, young children without pediatric guidance, uncontrolled diabetes or morning hypoglycemia patterns, hypotension, sedative stacking, fluvoxamine use, and safety-sensitive work that starts early. Melatonin gummies should be stored away from children because accidental pediatric ingestions have risen sharply in US poison-center data.
Melatonin is not being scored as a sleep-only report. Circadian rhythm, jet lag, pediatric sleep contexts, antioxidant biology, anxiety around surgery, immune-function, and prenatal caution all affect the use-case map.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Circadian Rhythm / Chronobiology: 7.8/10
Score: 7.8/10Melatonin is strongest for circadian-rhythm timing because the signal is directly tied to phase response, blind free-running rhythms, jet lag, and delayed sleep phase. The phase-response study found 0.5 mg and 3 mg doses produced similar phase shifts when timed correctly, with best advances when taken before DLMO (Burgess et al. 2010). Timing matters more than dose, which is exactly why this use case outranks generic insomnia. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Sleep Quality: 7.1/10
Score: 7.1/10Melatonin has a modest but repeatable sleep-quality effect, especially when the problem is timing rather than heavy sedation need. The PLoS One meta-analysis of 19 RCTs found sleep-onset latency improved by 7.06 minutes, total sleep time by 8.25 minutes, and sleep quality by SMD 0.22 (Ferracioli-Oda et al. 2013). The score is strong but not top tier because effect sizes are smaller than many expect. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Antioxidant / Oxidative Stress: 6.0/10
Score: 6.0/10Melatonin deserves a moderate antioxidant score because melatonin and its metabolites act in both water and lipid compartments and enter mitochondria. The broad pharmacology review summarizes antioxidant, circadian, and immune roles across tissues (Tordjman et al. 2017). Conventional dosing has stronger safety than proof of disease modification, so the score stays moderate rather than top tier. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Anxiety: 5.8/10
Score: 5.8/10Melatonin has a real but context-specific anxiety signal around surgery. A Cochrane review on preoperative and postoperative anxiety found melatonin can reduce preoperative anxiety compared with placebo, while postoperative findings were less consistent (Hansen et al. 2015). This score does not mean melatonin is a broad anxiolytic; it means perioperative anxiety has enough evidence to matter. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Immune Function: 5.0/10
Score: 5.0/10Melatonin has immune-function relevance through circadian and inflammatory biology, but conventional-dose human outcome data are mixed outside special populations. The ICU Cochrane review found limited evidence for sleep promotion in intensive-care adults (Lewis et al. 2018), and the later Pro-MEDIC trial did not reduce delirium. The use-case score is cautiously positive because the mechanism is broad while clinical outcomes remain uneven. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Prenatal (Maternal & Fetal Outcomes): 5.0/10
Score: 5.0/10Melatonin has prenatal biological interest because oxidative stress and circadian signaling matter in pregnancy, but conventional supplement use during pregnancy needs clinician oversight. This score is limited because the verified conventional-dose set does not include a strong pregnancy-outcomes RCT. The report keeps prenatal as a cautious research use case rather than using the retired pregnancy-safety slug, and the main practical advice is to avoid unsupervised use. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Pediatric Use: 6.7/10
Score: 6.7/10Melatonin has meaningful pediatric sleep evidence in autism and ADHD contexts, but pediatric use needs stricter oversight because accidental ingestion has become common. A meta-analysis in autism found sleep-onset latency improved by 39 minutes versus placebo and total sleep time improved by 44 minutes (Rossignol and Frye 2011). This score reflects supervised pediatric insomnia contexts, not casual gummy use. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence. Melatonin should therefore be treated as use-case-specific, with the strongest claims reserved for the endpoints named in the cited evidence.
Frequently Asked Questions
What does Melatonin actually do?
Melatonin acts through the pathway described in this report, and the best-supported effect is not the same for every use case. Melatonin should be matched to the strongest evidence rather than treated as a universal wellness tool. Effects of exogenous melatonin on sleep is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
How much Melatonin is used in studies?
Melatonin dosing depends on route and use case, with clinical ranges listed in the dosing block rather than inferred from community practice. Melatonin becomes riskier when anecdotal dose escalation outruns the monitored study context. Meta-analysis is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
How fast does Melatonin work?
Melatonin can produce some signals quickly, but the timeline depends on whether the target is sleepiness, circadian timing, pigmentation, libido, inflammation, or disease outcomes. Melatonin should be judged by the endpoint being tracked, not by a generic onset claim. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
Is Melatonin safe long term?
Melatonin has a different long-term safety answer by product quality, dose, route, and population. Melatonin looks more defensible when monitored use resembles the evidence base and less defensible when gray-market or high-dose practice expands beyond the data. Melatonin for the prevention and treatment of jet lag is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
Who should avoid Melatonin?
Melatonin should be avoided by people whose risk factors match the report's Avoid If section, especially when monitoring is unavailable. Melatonin is research assistance, so contraindications, pregnancy, pediatric use, and medication interactions belong with a clinician. Effects of exogenous melatonin on sleep is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
What is the biggest misconception about Melatonin?
The biggest misconception is that Melatonin has one simple identity. Melatonin changes meaning by dose, route, indication, sourcing, and timing, which is why the report separates use-case scores instead of giving every claim the same confidence. Meta-analysis is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
What should someone track with Melatonin?
Melatonin should be tracked with the monitoring block because subjective benefit can arrive before safety signals are obvious. Melatonin tracking should include the relevant Pulse dimensions, red flags, and biomarkers rather than only asking whether it felt strong. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
Why did Melatonin get this BioHarmony score?
Melatonin scored where it did because the upside and downside are both real. Melatonin moves higher when evidence is replicated, monitoring is clear, and severe risks are rare; it moves lower when sourcing, safety, or replication problems dominate. Melatonin for the prevention and treatment of jet lag is the citation to start with for this specific question. In practice, Melatonin should be interpreted through dose, timing, population, and monitoring rather than a one-line yes-or-no claim.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Melatonin would move upward if newer independent trials clarified which adults get the biggest circadian and non-sleep benefits, and if supplement quality became more reliable. Melatonin would move downward if long-term pediatric or endocrine data found higher-than-expected problems, or if common gummy products continued to expose children and adults to inaccurate doses. The first dimensions to move would be Evidence Quality, Safety Risk, Bioindividuality, and Opportunity Cost.Melatonin also needs context because readers may approach the report from different goals: symptom relief, performance, risk reduction, or curiosity about a mechanism For durability, the key question is whether benefits persist after the early window.The score does not tell a reader to use Melatonin; the score shows where the evidence, practical burden, and safety concerns currently meet For durability, the key question is whether benefits persist after the early window.That matters because the same intervention can look attractive in one subgroup and poorly matched in another For durability, the key question is whether benefits persist after the early window.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Better independent replication confirms the strongest claims. | Evidence +0.5, Efficacy +0.3, Safety unchanged. | 7.8 / 10 💪 Strong recommend |
| Long-term surveillance finds a clearer safety problem. | Safety +0.7, Reversibility +0.4, Evidence unchanged. | 6.6 / 10 👍 Worth trying |
| Quality-control data separates regulated use from gray-market use. | Safety -0.3, Cost -0.2, Effort -0.2. | 7.5 / 10 💪 Strong recommend |
| A large neutral RCT weakens the main claim. | Efficacy -0.5, Evidence +0.2, Breadth -0.3. | 6.8 / 10 👍 Worth trying |
| Better responder rules emerge. | Bioindividuality +0.5, Opportunity -0.2. | 7.7 / 10 💪 Strong recommend |
| Stronger dose and monitoring standards become routine. | Side Effects -0.3, Effort -0.3, Reversibility -0.2. | 7.4 / 10 💪 Strong recommend |
Melatonin lands at 7.3 / 10 💪 Strong recommend because the upside is real but conditional. The best use cases deserve attention, while the weaker use cases should stay research-only until better data changes the risk-benefit balance.
Key Evidence Sources
- Effects of exogenous melatonin on sleep: a meta-analysis. Sleep latency, total sleep time, and sleep efficiency.
- Meta-analysis: melatonin for the treatment of primary sleep disorders. Nineteen RCT sleep meta-analysis.
- Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- Melatonin for the prevention and treatment of jet lag. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- Human phase response curves to three days of daily melatonin. 0.5 mg vs 3 mg phase response.
- Entrainment of free-running circadian rhythms by melatonin in blind people. Blind free-running circadian rhythm RCT.
- Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Autism sleep latency and total sleep time.
- Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. Pediatric prolonged-release RCT.
- Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability. Supplement quality variability.
- Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Ferracioli-Oda 2013: Meta-analysis: melatonin for the treatment of primary sleep disorders.
Pre-RCT-Era Pharmacology and Use
Citations: Effects of exogenous melatonin on sleep: a meta-analysis, Human phase response curves to three days of daily melatonin, Evidence for the efficacy of melatonin in the treatment of primary ...
Traditional Medicine Systems
Citations: Effects of exogenous melatonin on sleep: a meta-analysis, Human phase response curves to three days of daily melatonin, Evidence for the efficacy of melatonin in the treatment of primary ...
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Fasting Glucose Baseline (pre-protocol) During | Expected Stable
- Blood Pressure Baseline (pre-protocol) During | Expected Watch
Pulse Dimensions to Watch
- Sleep During | Expected Up | Primary
- Energy During | Expected Watch | Secondary
- Calm During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Sleep Latency Scale 1-5 | During | Expected Down
- Morning Grogginess Scale 1-5 | During | Expected Watch
- Dream Intensity Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Mania, hypomania, severe mood change, or dangerous next-day sedation
- Repeated low blood pressure, falls, fainting, or worsening glucose control
- Accidental pediatric ingestion or use during pregnancy without clinician oversight
Other interventions for Circadian Rhythm
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.895 − 0.622 = 2.273
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.273 / 5) × 5 = 7.3 / 10
Further learning
Megadosing Melatonin Ultimate Guide: 11 Benefits, Protocols, Side Effects & More
Most people know melatonin as the “sleep hormone,” but at higher doses it does far more than regulate bedtime. This article breaks down the…
Melatonin, Methylene Blue, Mitochondria, & Pioneering Regenerative Medicine
Unlock your peak performance with Dr. John Lieurance of MitoZen Scientific. Discover the power of bioharmonizing your body through cutting-edge treatments like melatonin, methylene…
